FDA Expands Approval for Bladder Cancer Combination Therapy

The U.S. Food and Drug Administration has broadened the approval for a combination therapy involving pembrolizumab and enfortumab vedotin-ejfv for muscle-invasive bladder cancer. This expanded indication now includes all eligible adult patients, not just those who were cisplatin-ineligible, allowing for neoadjuvant and adjuvant treatment options. The decision provides more comprehensive treatment pathways for individuals facing this aggressive form of cancer.